December 12, 2022
Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader
American Society of Hematology Annual Meeting and Expo
CTCL
Read More
December 11, 2022
Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the treatment of Acute Myeloid Leukemia
American Society of Hematology Annual Meeting
Liquid Tumors
Read More
December 7, 2022
Proteomics enabling TPD Drug Discovery
TPD Assay Development and Screening Summit
Read More
October 27, 2022
Discovery of a First-In-Class MDM2 Degrader for the Treatment of Relapsed/Refractory TP-53 Wt AML & Solid Tumors
5th Annual Targeted Protein Degradation (TPD) Summit
Liquid Tumors
Solid Tumors
Read More
October 26, 2022
The Phase 1 Healthy Volunteer Clinical Trial of KT-474
5th Annual Targeted Protein Degradation (TPD) Summit
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
October 26, 2022
Development and Performance of Pharmacodynamic Assays to Demonstrate Proof-of-Mechanism for IRAK4 Degraders in a Phase1 Study
5th Annual Targeted Protein Degradation (TPD) Summit
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
October 25, 2022
Expression & Characterization of Novel Tissue Selective E3 Ligases
5th Annual Targeted Protein Degradation (TPD) Summit
Read More
October 19, 2022
KT-333, A First-in-Class STAT3 Degrader, Caused Strong STAT3 Degradation and Consistent Downstream Biology In Vitro and In Vivo
20th Annual Discovery on Target Conference
Liquid Tumors
Solid Tumors
Read More
August 24, 2022
Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications
ACS Fall 2022
MYD88 Tumors
Read More
August 15, 2022
MQAtlas Creates a Deep, Accurate and Global E3 Expression Atlas Enabling Targeted Protein Degradation Based Precision Medicine
The 14th International Symposium on Mass Spectrometry in the Health and Life Sciences
Read More